Navigation Links
Proteolix to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting
Date:10/17/2009

Location: Philadelphia Marriott Downtown, Salon H

  • Proteasome Inhibitors Block Production of Alpha Interferon and B Cell Activation (Presentation #579)

Sunday, October 18, 2009 at 5:30 p.m. ET

Plenary Session

Location: Pennsylvania Convention Center 204 B

  • Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus (Presentation #642)

Poster Presentations

Monday, October 19, 2009: 9:00 a.m. - 11:00 a.m. ET

Location: Pennsylvania Convention Center Hall D

  • The Selective Immunoproteasome Inhibitor PR-957 Blocks Production of Inflammatory Cytokines by Polarized Th1 and Th17 Cells without Affecting TGF-B Production by Regulatory T-Cells (Presentation #1080)

About Carfilzomib

Carfilzomib is the first in a new class of highly specific proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic and solid tumors, including multiple myeloma and renal cancer. Proteolix is currently conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including two ongoing Phase 2 clinical trials of single-agent carfilzomib, one in heavily pre-treated relapsed and refractory patients with progressive disease who have failed to respond to prior treatment, and a second in relapsed patients stratified by prior treatment with bortezomib. A Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, based on promising Phase 1 results, Proteolix is conducting a single-agent Phase 1b/2 c
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
5. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
8. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
9. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...tlinker.comannouncesthatanewmarketresearchreportis...ms&Equipment-AGlobalMarketPerspective ,, ...n-Systems--Equipment---A-Global-Market-Perspective...utm_campaign=prnewswire ,, Steamsterilizati...ure.Steamsterilizationmarketisstableduetoregulator...
(Date:11/23/2009)...tlinker.comannouncesthatanewmarketresearchreportis...les-AWorldMarketReview ,, http://www.reportl...d-Market-Review.html#utm_source=prnewswire&utm...lobalgeneralanesthesiadisposablesmarketischaracter...lerisewitnessedingeneralsurgicalprocedures,growing...
(Date:11/23/2009)...--LightSciencesOncology,Inc.(LSO)todayannouncedthe...oanewlycreatedseatonitsboardofdirectors.Mr.Seddigh...anies,includingElekta,tomarketleadership. ,, "T...hinbusinessdevelopmenttotheboard,"saidLSO,sChairma...cancer-therapybusinessdevelopment.Hehasoverseenthe...
Breaking Medicine Technology:Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 2Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 3Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 4Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 5Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 6Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 7Reportlinker Adds Anesthesia Disposables - A World Market Review 2Reportlinker Adds Anesthesia Disposables - A World Market Review 3Reportlinker Adds Anesthesia Disposables - A World Market Review 4Reportlinker Adds Anesthesia Disposables - A World Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 6Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2UCLA scientists make paralyzed rats walk again after spinal cord injury 9985 1UCLA scientists make paralyzed rats walk again after spinal cord injury 9985 2Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 57710 1Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 57710 2Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 57710 3Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 57710 4Optics made to measure 14158 1Optics made to measure 14158 2Optics made to measure 14158 3
..., April 15 Cardium Therapeutics,(Amex: CXM ) and...today that,positive findings from a preclinical st...arly rapid hyperthermia (cooling) for the potentia...attack), has been published,online by BioMed Centr...l,10, 2008)., (Photo: http://www.newscom.com/cgi...
...leoside-Sparing Regimen Designed to Avoid Risk of ...ass of HIV Drugs, KENILWORTH, N.J., April 15 Sch...nced that it has initiated a Phase II,clinical stu...onist, for,use in first-line therapy of adult trea...us only. Vicriviroc is a next-generation HIV entry...
Other Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
(Date:11/23/2009)...3/PRNewswire/--XiotechCorporationtodayannouncedtha...TM)7000storagesystem,poweredbyIntelligentStorageEl...orageneeds,enablefuturegrowthanddeliversignificant...enter. ,, MasonGeneral,locatedinShelton,Wash.,w...,s"MostWired-Rural"hospitalsin2008and2009foritssup...
(Date:11/23/2009)...lants need longer-term support than most friends, ..., according to a study of 160 patients published i...dvanced Nursing . , Researchers surveyed 55 ...r, together with 105 who had had surgery in the la... Center in Tennessee, USA. They wanted to see if t...
(Date:11/23/2009)...ically modified to produce bacterial proteins that..., have been planted on more than 200 million hecta...amed after the bacterium Bacillus thuringiensis ,..., allowing farmers to save money and lessen enviro... However, since insects can evolve resistance to ...
(Date:11/23/2009)...t explain why more blacks die than whites, study f...) -- Body weight and co-existing health problems d...lower survival rates than whites, U.S. researchers...ve lower survival rates than whites for nearly all...ave explored a variety factors, such as difference...
(Date:11/23/2009)...nn.,Nov.23/PRNewswire/--HealthLeaders-InterStudy,a...ortsthatself-insuredmembercompaniesthatarepartofMi...ggregatehealthcare-costdecreaseof1.5percentperheal...high-performanceprovidernetwork.Accordingtothe Mil...nsuredmembercompaniessaved$44millioninhealthcareco...
Breaking Medicine News(10 mins):Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Milwaukee Employers See Cost Savings with High-Performance Provider Network 2
...nc. (Nasdaq:,ICAD), an industry-leading provider o... early identification of cancer, today announced t... with the private equity,firm, Welsh, Carson, Ande...mber of directors to eight. Mr. Ecock, age,46, bri...
... with New President, Congress on,Public-Private Ef...h Care,Payment Systems to Emphasize Wellness, Evid... of chief,executives from many of the nation,s lea...th care gap, between the status,quo and the ,healt...
...] Scientists at the Swedish medical university Kar...n that a receptor called ALK7 plays important role... as the release of insulin from beta-cells in the ...moving the ALK7 receptor improves insulin release ...
...ess Releases its 2007 Claims Review from,Leading I...ion Data,, PORTLAND, Maine, May 13 Data from the...d today by the Council for,Disability Awareness (C...ng-term disabilities has grown four times,the grow...
...-PRNewswire-FirstCall/ -- China Sky One,Medical, I...C Bulletin,Board: CSKI), a leading fully integrate...e-counter drugs in the People,s Republic of China,...aldorf Astoria in New York City., Mr. Yanqing Liu...
... Promising results from a team of NewYork-Presbyte...an-scientists show that gene therapy is both safe ... disease, or Late Infantile Neuronal Ceroid Lipofu...rial found that the procedure -- which involves in...
Other Medicine News:Health News:iCAD, Inc. Appoints Anthony F. Ecock to Board of Directors 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 3Health News:Novel mechanisms controlling insulin release and fat deposition discovered 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 3Health News:China Sky One Medical, Inc. to Present at Brean Murray Carret & Co. All-Cap All-China Conference 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: